Vollenweider FX - Search Results

1

Modulating the rate and rhythmicity of perceptual rivalry alternations with the mixed 5-HT2A and 5-HT1A agonist psilocybin.

Carter OL, Pettigrew JD, Hasler F, Wallis GM, Liu GB, Hell D, Vollenweider FX. Carter OL, et al. Among authors: vollenweider fx. Neuropsychopharmacology. 2005 Jun;30(6):1154-62. doi: 10.1038/sj.npp.1300621. Neuropsychopharmacology. 2005. PMID: 15688092 Free article. Clinical Trial.

2

Psilocybin-induced changes in cerebral blood flow are associated with acute and baseline inter-individual differences.

Rieser NM, Gubser LP, Moujaes F, Duerler P, Lewis CR, Michels L, Vollenweider FX, Preller KH. Rieser NM, et al. Among authors: vollenweider fx. Sci Rep. 2023 Oct 14;13(1):17475. doi: 10.1038/s41598-023-44153-z. Sci Rep. 2023. PMID: 37838755 Free PMC article.

3

Functional brain networks reflect spatial and temporal autocorrelation.

Shinn M, Hu A, Turner L, Noble S, Preller KH, Ji JL, Moujaes F, Achard S, Scheinost D, Constable RT, Krystal JH, Vollenweider FX, Lee D, Anticevic A, Bullmore ET, Murray JD. Shinn M, et al. Among authors: vollenweider fx. Nat Neurosci. 2023 May;26(5):867-878. doi: 10.1038/s41593-023-01299-3. Epub 2023 Apr 24. Nat Neurosci. 2023. PMID: 37095399

4

Psychedelics and fNIRS neuroimaging: exploring new opportunities.

Scholkmann F, Vollenweider FX. Scholkmann F, et al. Among authors: vollenweider fx. Neurophotonics. 2023 Jan;10(1):013506. doi: 10.1117/1.NPh.10.1.013506. Epub 2022 Dec 2. Neurophotonics. 2023. PMID: 36474478 Free PMC article.

5

Differential psychopathology and patterns of cerebral glucose utilisation produced by (S)- and (R)-ketamine in healthy volunteers using positron emission tomography (PET).

Vollenweider FX, Leenders KL, Oye I, Hell D, Angst J. Vollenweider FX, et al. Eur Neuropsychopharmacol. 1997 Feb;7(1):25-38. doi: 10.1016/s0924-977x(96)00042-9. Eur Neuropsychopharmacol. 1997. PMID: 9088882 Clinical Trial.

6

Determination of psilocin and 4-hydroxyindole-3-acetic acid in plasma by HPLC-ECD and pharmacokinetic profiles of oral and intravenous psilocybin in man.

Hasler F, Bourquin D, Brenneisen R, Bär T, Vollenweider FX. Hasler F, et al. Among authors: vollenweider fx. Pharm Acta Helv. 1997 Jun;72(3):175-84. doi: 10.1016/s0031-6865(97)00014-9. Pharm Acta Helv. 1997. PMID: 9204776 Clinical Trial.

7

Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action.

Vollenweider FX, Vollenweider-Scherpenhuyzen MF, Bäbler A, Vogel H, Hell D. Vollenweider FX, et al. Among authors: vollenweider scherpenhuyzen mf. Neuroreport. 1998 Dec 1;9(17):3897-902. doi: 10.1097/00001756-199812010-00024. Neuroreport. 1998. PMID: 9875725 Clinical Trial.

8

5-HT modulation of dopamine release in basal ganglia in psilocybin-induced psychosis in man--a PET study with [11C]raclopride.

Vollenweider FX, Vontobel P, Hell D, Leenders KL. Vollenweider FX, et al. Neuropsychopharmacology. 1999 May;20(5):424-33. doi: 10.1016/S0893-133X(98)00108-0. Neuropsychopharmacology. 1999. PMID: 10192823 Clinical Trial.

9

Opposite effects of 3,4-methylenedioxymethamphetamine (MDMA) on sensorimotor gating in rats versus healthy humans.

Vollenweider FX, Remensberger S, Hell D, Geyer MA. Vollenweider FX, et al. Psychopharmacology (Berl). 1999 Apr;143(4):365-72. doi: 10.1007/s002130050960. Psychopharmacology (Berl). 1999. PMID: 10367553 Clinical Trial.

10

Mood state and brain electric activity in ecstasy users.

Gamma A, Frei E, Lehmann D, Pascual-Marqui RD, Hell D, Vollenweider FX. Gamma A, et al. Among authors: vollenweider fx. Neuroreport. 2000 Jan 17;11(1):157-62. doi: 10.1097/00001756-200001170-00031. Neuroreport. 2000. PMID: 10683849 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

154 results

Search Page

Filters